yulius hermanto
Transdermal Patch for Alzheimer's Disease
People are tend to live longer, actually this maybe a good news for mankind.
But, the more old someone, more vulnerable to degenerative disease. Neurodegenerative disease has become main concern in health care lately, because lack of understanding of brain and neural complexity compare to heart and endocrine system.
The neurodegenerative disease tend to be chronic and debilitating, thus leads to poor quality of life. Lack of understanding of brain and neural system makes therapy of neurodegenerative tend to be supportive not eliminate the causes.
Alzheimer's Disease, one of the neurodegenerative disease with the highest prevalence compare to others. Alzheimer's disease is the most common form of dementia among older people. Dementia is a brain disorder that seriously affects a person's ability to carry out daily activities.
Alzheimer begins slowly. It first involves the parts of the brain that control thought, memory and language. People with Alzheimer may have trouble remembering things that happened recently or names of people they know.
In Alzheimer, over time, symptoms get worse. People may not recognize family members or have trouble speaking, reading or writing. They may forget how to brush their teeth or comb their hair. Later on, they may become anxious or aggressive, or wander away from home. Eventually, they need total care. This can cause great stress for family members who must care for them.
Alzheimer usually begins after age 60. The risk goes up as you get older. Your risk is also higher if a family member has had the disease. No treatment can stop the disease. However, some drugs may help keep symptoms from getting worse for a limited time
Transdermal Patch Technology
Current understanding of Alzheimer, scientist found that in Alzheimer there is a decreased of cholinergic neurotransmitter. Cholinergic neurotransmitter is needed in memory functioning. So, most of the drugs of Alzheimer aim at increasing cholinergic neurotransmitter.
Until now, Alzheimer is treated by improving brain function and slowing the disease process. But, it's difficult to stop disease process or restore brain function.
Recent technology about drugs in Alzheimer is a transdermal patch to administer cholinesterase inhibitor (ChEI)–based therapy. The study showed that caregivers who administered the transdermal rivastigmine patch were able to treat patients even on "bad days." Furthermore, the patch was associated with less caregiver anxiety and reduced the considerable effort often required to administer medication orally.
In addition, caregivers often described patient deterioration as having slowed or stopped. Many also described patients as being more relaxed and less anxious on the patch and that it improved long-term memory and, in some instances, language function.
With growing recognition of the importance of early initiation of ChEI-based therapy and the need to achieve therapeutic doses quickly, reasons for any delays in treatment initiation need to be fully explored.
The investigators also claim that drug delivery is also smoother and more continuous with the patch, which might account for some of the improvements in deterioration reported by some caregivers.
However, it has a number of negative side effects as well, including rashes, dry and itchy skin, and skin peeling in the patch administration area, and these effects can cause patients to rip the patch off prematurely, stopping drug administration to the system.
But, the more old someone, more vulnerable to degenerative disease. Neurodegenerative disease has become main concern in health care lately, because lack of understanding of brain and neural complexity compare to heart and endocrine system.
The neurodegenerative disease tend to be chronic and debilitating, thus leads to poor quality of life. Lack of understanding of brain and neural system makes therapy of neurodegenerative tend to be supportive not eliminate the causes.
Alzheimer's Disease, one of the neurodegenerative disease with the highest prevalence compare to others. Alzheimer's disease is the most common form of dementia among older people. Dementia is a brain disorder that seriously affects a person's ability to carry out daily activities.
Alzheimer begins slowly. It first involves the parts of the brain that control thought, memory and language. People with Alzheimer may have trouble remembering things that happened recently or names of people they know.
In Alzheimer, over time, symptoms get worse. People may not recognize family members or have trouble speaking, reading or writing. They may forget how to brush their teeth or comb their hair. Later on, they may become anxious or aggressive, or wander away from home. Eventually, they need total care. This can cause great stress for family members who must care for them.
Transdermal Patch Technology
Current understanding of Alzheimer, scientist found that in Alzheimer there is a decreased of cholinergic neurotransmitter. Cholinergic neurotransmitter is needed in memory functioning. So, most of the drugs of Alzheimer aim at increasing cholinergic neurotransmitter.
Until now, Alzheimer is treated by improving brain function and slowing the disease process. But, it's difficult to stop disease process or restore brain function.
Recent technology about drugs in Alzheimer is a transdermal patch to administer cholinesterase inhibitor (ChEI)–based therapy. The study showed that caregivers who administered the transdermal rivastigmine patch were able to treat patients even on "bad days." Furthermore, the patch was associated with less caregiver anxiety and reduced the considerable effort often required to administer medication orally.
In addition, caregivers often described patient deterioration as having slowed or stopped. Many also described patients as being more relaxed and less anxious on the patch and that it improved long-term memory and, in some instances, language function.
With growing recognition of the importance of early initiation of ChEI-based therapy and the need to achieve therapeutic doses quickly, reasons for any delays in treatment initiation need to be fully explored.
The investigators also claim that drug delivery is also smoother and more continuous with the patch, which might account for some of the improvements in deterioration reported by some caregivers.
However, it has a number of negative side effects as well, including rashes, dry and itchy skin, and skin peeling in the patch administration area, and these effects can cause patients to rip the patch off prematurely, stopping drug administration to the system.
